PL1608965T3 - Sposoby wyznaczania skuteczności terapii chorób zapalnych jelit - Google Patents
Sposoby wyznaczania skuteczności terapii chorób zapalnych jelitInfo
- Publication number
- PL1608965T3 PL1608965T3 PL04749582T PL04749582T PL1608965T3 PL 1608965 T3 PL1608965 T3 PL 1608965T3 PL 04749582 T PL04749582 T PL 04749582T PL 04749582 T PL04749582 T PL 04749582T PL 1608965 T3 PL1608965 T3 PL 1608965T3
- Authority
- PL
- Poland
- Prior art keywords
- bowel
- treatments
- methods
- inflammatory diseases
- determining efficacy
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/404,512 US20040197304A1 (en) | 2003-04-01 | 2003-04-01 | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
| PCT/US2004/009865 WO2004090539A2 (en) | 2003-04-01 | 2004-03-31 | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
| EP04749582.5A EP1608965B1 (en) | 2003-04-01 | 2004-03-31 | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1608965T3 true PL1608965T3 (pl) | 2014-01-31 |
Family
ID=33096943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04749582T PL1608965T3 (pl) | 2003-04-01 | 2004-03-31 | Sposoby wyznaczania skuteczności terapii chorób zapalnych jelit |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20040197304A1 (pl) |
| EP (1) | EP1608965B1 (pl) |
| JP (1) | JP2006521537A (pl) |
| CN (1) | CN1764838A (pl) |
| CA (1) | CA2521136A1 (pl) |
| ES (1) | ES2435848T3 (pl) |
| MX (1) | MXPA05010634A (pl) |
| PL (1) | PL1608965T3 (pl) |
| WO (1) | WO2004090539A2 (pl) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10118446A1 (de) * | 2001-04-12 | 2002-10-17 | Thomas Hartung | Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen |
| US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
| US7651684B2 (en) | 2001-12-07 | 2010-01-26 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
| US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
| US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
| KR100811995B1 (ko) | 2001-12-07 | 2008-03-10 | 사이토리 테라퓨틱스, 인크. | 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법 |
| US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| US8105580B2 (en) | 2001-12-07 | 2012-01-31 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to promote wound healing |
| US7862808B2 (en) * | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| JP2008520684A (ja) | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Ｉｌ−１３に対する完全ヒトモノクローナル抗体 |
| US7303745B2 (en) | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| WO2010021993A1 (en) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
| WO2010108908A1 (en) * | 2009-03-24 | 2010-09-30 | Transgene Sa | Biomarker for monitoring patients |
| WO2010124235A1 (en) * | 2009-04-23 | 2010-10-28 | Cytori Therapeutics, Inc. | Use adipose tissue-derived regenerative cells in the modulation of inflammation in the pancreas and in the kidney |
| WO2010127310A1 (en) | 2009-05-01 | 2010-11-04 | Cytori Therapeutics, Inc. | Systems, methods and compositions for optimizing tissue and cell enriched grafts |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| WO2012154987A1 (en) | 2011-05-10 | 2012-11-15 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| CN102279257B (zh) * | 2011-06-27 | 2014-02-19 | 刘永庆 | 一种用于诊断人或动物的免疫相关性疾病的试剂盒 |
| EP3549534B1 (en) | 2011-07-12 | 2022-01-12 | Ircad | Modular magnetic anastomosis device |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| CN102621331B (zh) * | 2012-04-05 | 2014-07-30 | 中国医学科学院病原生物学研究所 | 一种检测或辅助检测结核性胸膜炎的试剂盒 |
| ES2638971T3 (es) * | 2012-10-05 | 2017-10-24 | Nestec S.A. | Métodos para predecir y monitorizar la cicatrización de la mucosa |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| CN105308460A (zh) * | 2013-05-02 | 2016-02-03 | 天主教大学基金会 | 个性化药物 |
| JP2017500285A (ja) | 2013-11-04 | 2017-01-05 | ユーティーアイ リミテッド パートナーシップ | 持続的免疫療法のための方法および組成物 |
| SG10201913957PA (en) | 2015-05-06 | 2020-03-30 | Uti Lp | Nanoparticle compositions for sustained therapy |
| CN108135946A (zh) | 2015-08-27 | 2018-06-08 | 宝洁公司 | 长双歧杆菌 |
| US11162943B2 (en) | 2017-05-31 | 2021-11-02 | Prometheus Biosciences Inc. | Methods for assessing mucosal healing in Crohn's disease patients |
| JP7436372B2 (ja) | 2017-11-29 | 2024-02-21 | ユーティアイ・リミテッド・パートナーシップ | 自己免疫性疾患を治療する方法 |
| KR102158759B1 (ko) * | 2018-11-29 | 2020-09-22 | 주식회사 카인사이언스 | 사이토카인 분석을 통한 관절염 치료제 스크리닝 방법 |
| JP7013419B2 (ja) * | 2019-08-07 | 2022-02-15 | 日清食品ホールディングス株式会社 | 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌 |
| CN112786113A (zh) * | 2019-11-07 | 2021-05-11 | 特安康股份有限公司 | 个体化益生菌数据库的建立方法及其应用在益生菌的筛选 |
| WO2021087890A1 (zh) * | 2019-11-07 | 2021-05-14 | 特安康股份有限公司 | 个体化益生菌数据库的建立方法及其应用在益生菌的筛选 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| WO1994004180A2 (en) | 1992-08-20 | 1994-03-03 | Schering Corporation | Novel uses of il-4 and/or il-10, and antibodies against the same |
| US5853697A (en) * | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| PT862863E (pt) | 1997-01-09 | 2002-04-29 | Nestle Sa | Produto cerealifero contendo probioticos |
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| PL207930B1 (pl) * | 2000-05-25 | 2011-02-28 | Nestle Sa | Zastosowanie wyizolowanego probiotycznego szczepu bakterii kwasu mlekowego o aktywności probiotycznej, kompozycja pokarmowa i izolowany szczep bakterii kwasu mlekowego |
| ATE419331T1 (de) | 2000-08-25 | 2009-01-15 | Wakamoto Pharma Co Ltd | L. salivarius-stamm enthaltende probiotische produkte |
| US20020141977A1 (en) | 2001-04-02 | 2002-10-03 | Collins John Kevin | Immunotherapy based on dendritic cells |
| PE20030283A1 (es) | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| US20030092163A1 (en) | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| PE20030274A1 (es) | 2001-07-26 | 2003-05-08 | Alimentary Health Ltd | Cepas de lactobacillus salivarius |
-
2003
- 2003-04-01 US US10/404,512 patent/US20040197304A1/en not_active Abandoned
-
2004
- 2004-03-26 US US10/810,358 patent/US7923000B2/en not_active Expired - Fee Related
- 2004-03-31 JP JP2005518927A patent/JP2006521537A/ja active Pending
- 2004-03-31 WO PCT/US2004/009865 patent/WO2004090539A2/en not_active Ceased
- 2004-03-31 ES ES04749582T patent/ES2435848T3/es not_active Expired - Lifetime
- 2004-03-31 CN CNA2004800081499A patent/CN1764838A/zh active Pending
- 2004-03-31 MX MXPA05010634A patent/MXPA05010634A/es unknown
- 2004-03-31 PL PL04749582T patent/PL1608965T3/pl unknown
- 2004-03-31 EP EP04749582.5A patent/EP1608965B1/en not_active Expired - Lifetime
- 2004-03-31 CA CA002521136A patent/CA2521136A1/en not_active Abandoned
-
2011
- 2011-02-28 US US13/036,109 patent/US8216563B2/en not_active Expired - Fee Related
-
2012
- 2012-06-15 US US13/524,020 patent/US20130217600A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1608965A2 (en) | 2005-12-28 |
| CA2521136A1 (en) | 2004-10-21 |
| US20130217600A1 (en) | 2013-08-22 |
| MXPA05010634A (es) | 2005-12-12 |
| US7923000B2 (en) | 2011-04-12 |
| US8216563B2 (en) | 2012-07-10 |
| US20040197304A1 (en) | 2004-10-07 |
| CN1764838A (zh) | 2006-04-26 |
| EP1608965B1 (en) | 2013-08-28 |
| WO2004090539A2 (en) | 2004-10-21 |
| WO2004090539A3 (en) | 2004-12-23 |
| US20110152117A1 (en) | 2011-06-23 |
| US20040228837A1 (en) | 2004-11-18 |
| ES2435848T3 (es) | 2013-12-23 |
| JP2006521537A (ja) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2402072B (en) | Ureter resectoscope | |
| ZA200508427B (en) | Methods for treating interleuking-6 related diseases | |
| GB0307918D0 (en) | Therapeutic use | |
| GB0303910D0 (en) | Therapeutic agents | |
| EP1592384A4 (en) | COP 1 FOR THE TREATMENT OF INFLAMMABLE ENDURANCE | |
| EP1667730A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASE | |
| GB0310401D0 (en) | Therapeutic agent | |
| GB0323378D0 (en) | Therapeutic agent | |
| GB0320238D0 (en) | Treatment of disease | |
| EP1708961A4 (en) | TREATMENT OF INFLAMMATORY ENDURANCE WITH ANTI-IP-10 ANTIBODIES | |
| GB0301350D0 (en) | Therapeutic agents | |
| GB0314136D0 (en) | Therapeutic agents | |
| EP1805210A4 (en) | NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | |
| EP1444983A4 (en) | AGENTS FOR THE TREATMENT OF INFLAMMATORY ABDOMINAL DISEASES | |
| IL173068A0 (en) | Acute inflammatory condition treatment | |
| GB0526394D0 (en) | Treatment of inflammatory diseases | |
| GB0327975D0 (en) | Methods of treatment | |
| IL172061A0 (en) | Further therapeutic use of zolpidem | |
| GB0307333D0 (en) | Therapeutic agent | |
| AU2003902452A0 (en) | Treatment of inflammatory bowel disease | |
| GB0411302D0 (en) | Treatment of inflammatory diseases | |
| GB0411301D0 (en) | Treatment of inflammatory disease | |
| HU0302933D0 (en) | Treatment of diseases | |
| AU2002952084A0 (en) | Treatment of inflammatory bowel disease | |
| GB0322921D0 (en) | Methods of treatment |